VKTX — Viking Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.19bn
- $3.48bn
- 59
- 21
- 34
- 31
Annual cashflow statement for Viking Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -39.5 | -55 | -68.9 | -85.9 | -110 |
| Non-Cash Items | 10 | 10.3 | 10.3 | 8.97 | 12.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.72 | -2.93 | 10.2 | 3.55 | 9.36 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -21.8 | -47.6 | -48.4 | -73.4 | -87.8 |
| Other Investing Cash Flow Items | 41.6 | 38 | 54.8 | -179 | -553 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 41.6 | 38 | 54.8 | -179 | -553 |
| Financing Cash Flow Items | -0.322 | -0.753 | 10.1 | 265 | 602 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.95 | 6.88 | 4.16 | 271 | 612 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.7 | -2.75 | 10.3 | 18.9 | -28.8 |